Hepatitis B immune globulin and HBV-related liver transplantation

Abstract

The risk of recurrence of liver cirrhosis and hepatocellularcarcinoma due to hepatitis B virus (HBV) infection was 90%following liver transplantation before 1990’s but now we rarelysee recurrence due to the highly effective prophylactic treatments.In this review, we discussed the achievements of the prophylactictreatments in patients transplanted for HBV diseases. Options forhyperimmune globulin usage and high genetic barier anti-viraldrugs can be used to prevent the recurrence.Keywords: Liver transplant, Hepatitis B hyperimmune globulin,Recurrence

References

1. Poland GA, Jacobson RM. Clinical practice: prevention of
2. hepatitis B with the hepatitis B vaccine. N Engl J Med 2004
3. 2832-38.
4. Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting
5. list registration for liver transplantation for viral hepatitis in
6. the United States. Gastroenterology 2009; 137:1680–6.
7. Villamil FG. Prophylaxis with anti-HBs immune globulins
8. and nucleoside analogues after liver transplantation for HBV

9. infection.
10. J Hepatol 2003; 39: 466-74.
11. Samuel D, Bismuth A, Mathieu D, et al. Passive
12. immunoprophylaxis after liver transplantation in HBsAgpositive
13. patients. Lancet 1991; 337: 813-5.
14. Lauchart W, Muller R, Pichlmayr R. Long-term
15. immunoprophylaxis of hepatitis B virus reinfection in
16. recipients of human liver allografts. Transplant Proc 1987
17. 4051-3.
18. Lok A. Prevention of recurrent hepatitis B post-liver
19. transplantation. Liver Transpl 2002; 8: S67-73.
20. Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy
21. is effective in suppressing hepatitis B virus after liver
22. transplantation. Gastroenterology 2011; 141: 1212-9.
23. Previsani N, Lavanchy D, Zuckerman AJ. Hepatitis B. Viral
24. hepatitis. In: Mushawar IK, editor. Perspectives in Medical
25. Virology, vol. 10. Amsterdam: Elsevier, 2004: 31-98.
26. McGory RW, Ishitani MB, Oliveira WM, et al. Improved
27. outcome of orthotopic liver transplantation for chronic
28. hepatitis B cirrhosis with aggressive passive immunization.
29. Transplantation 1996; 61: 1358-64.
30. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver
31. transplant recipients using a fixed dosing schedule of hepatitis
32. B immunoglobulin. Hepatology 1996; 24: 1327-33.
33. Angus PW, Mc Caughan GW, Gane EJ, Crawford DH, Harley
34. H. Combination low-dose hepatitis B immune globulin and
35. lamivudine therapy provides effective prophylaxis against
36. posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-33.
37. Gane EJ, Angus PW, Strasser S, et al. Australasian liver
38. transplant study group. Lamivudine plus low-dose hepatitis
39. B immunoglobulin to prevent recurrent hepatitis B following
40. liver transplantation. Gastroenterology 2007; 132: 931-37.
41. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of
42. hepatitis B and C virus infections and risk factors in Turkey
43. a fieldwork TURHEP study. Clin Microbiol Infect 2015
44. 21:1020-6.
45. Karasu Z, Ozacar T, Akyildiz M, et al. Low-dose hepatitis B
46. immune globulin and higher-dose lamivudinee combination to
47. prevent hepatitis B virus recurrence after liver transplantation.
48. Antivir Ther 2004 ;9:921-7.
49. Karasu Z, Akyildiz M, Kilic M, et al. Living donor liver
50. transplantation for hepatitis B cirrhosis. J Gastroenterol
51. Hepatol 2007; 22: 2124-9.
52. Wong SN, Chu CJ, Wai CT, et al. Low risk of hepatitis
53. B recurrence after withdrawal of long-term hepatitis B
54. immunoglobulin in patients receiving maintenance nucleos(t)
55. ide analogue therapy. Liver Transpl 2007; 13: 374-81.
56. Teperman LW, Poordad F, Bzowej N, et al. Randomized trial
57. of emtricitabine/tenofovir disoproxil fumarate after hepatitis
58. B immunoglobulin withdrawal after liver transplantation.
59. Liver transplantation : official publication of the American
60. Association for the Study of Liver Diseases and the
61. International Liver Transplantation Society 2013;19:594-
62. Kim YK, Kim SH, Lee SD, Park SJ. Clinical outcomes
63. and risk factors of hepatitis B virus recurrence in patients
64. who received prophylaxis with entecavir and hepatitis B
65. immunoglobulin following liver transplantation. Transplant
66. Proc 2013; 45: 3052-6.
67. Na GH, Kim DG, Han JH, et al. Prevention and risk factors of
68. hepatitis B recurrence after living donor liver transplantation.
69. J Gastroenterol Hepatol 2014; 29: 151-6.
70. Ueda Y, Marusawa H, Kaido T, et al. Efficacy and safety of
71. prophylaxis with entecavir and hepatitis B immunoglobulin
72. in preventing hepatitis B recurrence after living-donor liver
73. transplantation. Hepatol Res 2013; 43: 67-71.
74. Jiménez-Pérez M, Sáez-Gómez AB, Mongil Poce L, et
75. al. Efficacy and safety of entecavir and/or tenofovir for
76. prophylaxis and treatment of hepatitis B recurrence post-liver
77. transplant. Transplant Proc 2010; 42: 3167-8.
78. Teperman LW, Poordad F, Bzowej N, et al. Randomized trial
79. of emtricitabine/tenofovir disoproxil fumarate after hepatitis
80. B immunoglobulin withdrawal after liver transplantation.
81. Liver Transpl 2013; 19: 594-601.
82. Teperman LSJ, Poordad F, Schiano T, et al. Randomized trial
83. of emtricitabine/tenofovir DF plus/minus HBIG withdrawal
84. in prevention of chronic hepatitis B recurrence post-liver
85. transplantation: 48 week results. Abstract presented at
86. American Transplant Congress, Philadelphia, 2011.
87. Cholongitas E, Goulis I, Antoniadis N, et al. New nucleos(t)
88. ide analogue monoprophylaxis after cessation of hepatitis B
89. immunoglobulin is effective against hepatitis B recurrence.
90. Transpl Int 2014;27:1022–8.
91. Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10
92. years after liver transplantation despite successful anti-HBs
93. passive immunoprophylaxis. Hepatology 2003;38:86-95.
94. Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus
95. PW. Combination of lamivudine and adefovir without
96. hepatitis B immune globulin is safe and effective prophylaxis
97. against hepatitis b virus recurrence in hepatitis b surface
98. antigen-positive liver transplant candidates. Liver Transpl
99. 19:268–74.
100. Fung J, Chan SC, Cheung C, et al. Oral nucleoside/
101. nucleotide analogs without hepatitis B immune globulin
102. after liver transplantation for hepatitis B. Am J Gastroenterol
103. 108:942–948.
104. Khemichian S, Hsieh MJ, Zhang SR, Limurti J, Kim J
105. Fong TL.Nucleoside-nucleotide analog combination therapy
106. is effective in preventing recurrent hepatitis B after liver
107. transplantation. Dig Dis Sci 2015 ;60:2807-12.
108. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy
109. and safety of entecavir versus adefovir in chronic hepatitis
110. B patients with hepatic decompensation: a randomized openlabel
111. study. Hepatology 2011;54:91–100.
112. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon
113. E, Colombo M. Low resistance to adefovir combined with
114. lamivudine: a 3-year study of 145 lamivudine-resistant
115. hepatitis B patients. Gastroenterology 2007;133: 1445–51.